Pulmonary Hypertension
Conditions
Keywords
Pulmonary hypertension in lung transplant recipients
Brief summary
This study seeks to demonstrate that Natrecor® (nesiritide) is safe and effective and has a favorable hemodynamic profile in lung transplant recipients that will allow for the avoidance of inhaled nitric oxide (iNO) use. It is estimated that the use of nesiritide will decrease the otherwise historically mandated use of iNO by 50%, as compared to the necessity of iNO use by matched historical controls.
Detailed description
A condition called ischemic reperfusion injury (IRI) occurs in all lung transplants. The amount of reperfusion injury varies from person to person. IRI occurs when the blood supply to tissue (in this case, transplanted lung(s)) is decreased and then is restored. IRI can cause a decrease in function in a newly transplanted lung. When this occurs, or when people have pulmonary hypertension (high blood pressure in your lungs), doctors use Nitric Oxide to improve the pressure and blood supply to the transplanted lung. Nitric Oxide (NO) is given by inhalation while patients are on a ventilator (breathing machine). Because NO must be given by a ventilator and because patients on ventilators must be in an intensive care unit, the cost of treating people with NO is very high. NO can also cause rebound pulmonary hypertension (high blood pressure in the lungs that reoccurs) when it is stopped. Because of these reasons, doctors are looking for other treatments for IRI and pulmonary hypertension. A drug called Natrecor has been shown to reduce pulmonary pressures in heart transplant patients. Doctors believe it may be helpful to lung transplant patients as well.
Interventions
DRUGNatrecor
Natrecor will be initiated as a bolus dose of 2 mcg/kg followed by a continuous infusion via infusion pump after induction of anesthesia but prior to incision. Natrecor infusion will be started at the recommended rate of 0.01mcg/kg/min. This dose may be adjusted by the investigator(s) only based on hemodynamic monitoring and pulmonary parameters. Study drug will be infused for a minimum of 24 hours and a maximum of 96 hours.
Sponsors
University of Wisconsin, Madison
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Single or double lung transplant or heart/lung transplant recipient * Planned use of Natrecor * Pulmonary artery (PA) systolic pressures \> 35
Exclusion criteria
* Previous lung transplant * Use of Prolastin after pneumonectomy * Mean arterial pressure of \< 55 * Known allergy or sensitivity to nesiritide * Females of childbearing potential with a positive pregnancy test or women who are breast feeding * Use of nesiritide, for any reason, within 30 days prior to transplant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the safety and efficacy of Natrecor® in reducing nitric oxide used perioperatively in patients undergoing single or double lung transplantation who have or are at risk for developing pulmonary hypertension | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare length of stay in the Intensive Care Unit (ICU) | — |
| To compare renal function as defined by peak serum creatinine and calculated creatinine clearance during the first 72 hours post-transplant | — |
| To compare necessity of CPB between Natrecor® versus nitric oxide | — |
| To compare hemodynamic parameters | — |
| To compare total cost-effective evaluation between patients receiving Natrecor and those who received iNO | — |
| To compare time to dry weight | — |
| To compare duration of mechanical ventilation | — |
| To compare pulmonary parameters | — |
| To compare IRI via chest x-ray and PAO2/FIO2 ratio | — |
| To compare length of stay (total) | — |
Countries
United States
Outcome results
None listed